vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $185.1M, roughly 1.8× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 13.2%, a 20.1% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs -2.7%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 0.4%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DOCS vs HAE — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $339.0M |
| Net Profit | $61.6M | $44.7M |
| Gross Margin | 89.9% | 59.7% |
| Operating Margin | 38.9% | 19.9% |
| Net Margin | 33.3% | 13.2% |
| Revenue YoY | 9.8% | -2.7% |
| Net Profit YoY | -18.1% | 19.3% |
| EPS (diluted) | $0.31 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $339.0M | ||
| Q3 25 | $168.5M | $327.3M | ||
| Q2 25 | $145.9M | $321.4M | ||
| Q1 25 | $138.3M | $330.6M | ||
| Q4 24 | $168.6M | $348.5M | ||
| Q3 24 | $136.8M | $345.5M | ||
| Q2 24 | $126.7M | $336.2M | ||
| Q1 24 | $118.1M | — |
| Q4 25 | $61.6M | $44.7M | ||
| Q3 25 | $62.1M | $38.7M | ||
| Q2 25 | $53.3M | $34.0M | ||
| Q1 25 | $62.5M | $58.0M | ||
| Q4 24 | $75.2M | $37.5M | ||
| Q3 24 | $44.2M | $33.8M | ||
| Q2 24 | $41.4M | $38.4M | ||
| Q1 24 | $40.6M | — |
| Q4 25 | 89.9% | 59.7% | ||
| Q3 25 | 90.3% | 59.5% | ||
| Q2 25 | 89.2% | 59.8% | ||
| Q1 25 | 89.5% | 58.4% | ||
| Q4 24 | 91.6% | 55.5% | ||
| Q3 24 | 90.0% | 54.2% | ||
| Q2 24 | 89.3% | 52.0% | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | 19.9% | ||
| Q3 25 | 37.8% | 17.9% | ||
| Q2 25 | 37.4% | 16.8% | ||
| Q1 25 | 35.2% | 21.6% | ||
| Q4 24 | 47.4% | 16.9% | ||
| Q3 24 | 38.8% | 15.0% | ||
| Q2 24 | 36.4% | 11.8% | ||
| Q1 24 | 35.5% | — |
| Q4 25 | 33.3% | 13.2% | ||
| Q3 25 | 36.8% | 11.8% | ||
| Q2 25 | 36.5% | 10.6% | ||
| Q1 25 | 45.2% | 17.5% | ||
| Q4 24 | 44.6% | 10.8% | ||
| Q3 24 | 32.3% | 9.8% | ||
| Q2 24 | 32.7% | 11.4% | ||
| Q1 24 | 34.4% | — |
| Q4 25 | $0.31 | $0.95 | ||
| Q3 25 | $0.31 | $0.81 | ||
| Q2 25 | $0.27 | $0.70 | ||
| Q1 25 | $0.31 | $1.17 | ||
| Q4 24 | $0.37 | $0.74 | ||
| Q3 24 | $0.22 | $0.66 | ||
| Q2 24 | $0.21 | $0.74 | ||
| Q1 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $979.3M | $911.5M |
| Total Assets | $1.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $363.4M | ||
| Q3 25 | $169.2M | $296.4M | ||
| Q2 25 | $137.3M | $292.9M | ||
| Q1 25 | $209.6M | $306.8M | ||
| Q4 24 | $165.3M | $320.8M | ||
| Q3 24 | $184.2M | $299.3M | ||
| Q2 24 | $111.4M | $344.4M | ||
| Q1 24 | $96.8M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $979.3M | $911.5M | ||
| Q3 25 | $1.1B | $849.2M | ||
| Q2 25 | $1.0B | $882.3M | ||
| Q1 25 | $1.1B | $820.8M | ||
| Q4 24 | $1.0B | $906.9M | ||
| Q3 24 | $961.2M | $878.9M | ||
| Q2 24 | $913.6M | $905.4M | ||
| Q1 24 | $901.4M | — |
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.2B | $2.5B | ||
| Q3 24 | $1.1B | $2.5B | ||
| Q2 24 | $1.1B | $2.5B | ||
| Q1 24 | $1.1B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 0.99× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $93.6M | ||
| Q3 25 | $93.9M | $111.3M | ||
| Q2 25 | $62.1M | $17.4M | ||
| Q1 25 | $98.5M | $116.6M | ||
| Q4 24 | $65.2M | $43.8M | ||
| Q3 24 | $68.3M | $48.8M | ||
| Q2 24 | $41.2M | $-27.4M | ||
| Q1 24 | $63.9M | — |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M | ||
| Q1 24 | — | — |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.0% | 1.7% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 0.99× | 2.09× | ||
| Q3 25 | 1.51× | 2.88× | ||
| Q2 25 | 1.16× | 0.51× | ||
| Q1 25 | 1.58× | 2.01× | ||
| Q4 24 | 0.87× | 1.17× | ||
| Q3 24 | 1.55× | 1.44× | ||
| Q2 24 | 1.00× | -0.71× | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
